ARKK Holdings of Veracyte (VCYT) - Updated Daily
BioinformaticsGenomics
Key Statistics
Statistics
| ⚖️Weighting | 🧢Market Cap |
|---|---|
| 1.37% | $1.55b |
| 🏋🏿♂️Weight Rank In ARKK | 🌏Country |
| 22 | 🇺🇸United States |
| 🏋️♀️Weight Rank Across All Funds | 💳ARK Estimated Cost Average |
| 22 | $14.27 |
| 🎫ARK Ownership Percent | |
| 6.6% | |
| Description | |
|---|---|
| Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company's growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company's tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte's exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. | |
| Website | |
| www.veracyte.com |
Other ETFs That Hold VCYT
Research Notes and Commentary for VCYT
December 15, 2020
Daily Ark Digest
Trading Floor
September 14, 2020
#239: Is the Marketing Department Running GM, & More
See Section #3March 22, 2020
R&D Should Be Considered an Asset, Not an Expense, Particularly in the Genomics Industry
See Section #5December 16, 2019